Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of [14C]-Opicapone in Healthy Males
NCT02169427Phase 1Completed
- Sponsor
- BIAL
- Start
- Mar 2011
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of opicapone in Parkinson's disease (PD), sponsored by BIAL. Primary endpoint: Cumulative Recovery of [14C]-Radioactivity. Started Mar 2011; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02169427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02169427.